Ferraris the growth stock - and it pays a dividend too!

Just finihed off some initial research on the US market for Cardivasular disease/monitoring.

Cardiovascular disease remains the leading cause of death in the US, heart disease and stroke are, respectively, the first and third leading causes of death in the United States. They are the principal causes of cardiovascular disease death and are also major causes of disability. The aging of the population will undoubtedly result in an increased incidence of chronic diseases, including coronary artery disease, heart failure and stroke. The U.S. Census estimates that there will be 40 million Americans age 65 and older in 2010.

Diabetes and obesity, both of which greatly increase heart disease risk, have seen explosive increases in prevalence. Their related complications — hypertension, hyperlipidemia and atherosclerotic vascular disease — also have increased.

According to the American Heart Association (AHA), 61,800,000 Americans have cardiovascular disease, which can include high blood pressure, coronary heart disease (heart attack and chest pain), stroke, birth defects of the heart and blood vessels, and congestive heart failure. The estimated direct costs of Cardiovascular Diseases and Stroke in the US for 2003 is $209 billion, of which $36.6 billion was medical durables (p40)-

Cardivascualr disease and its associated markets are already huge, and is set to experience (unfortunately) further growth, Ferraris appears well positioned to get a percentage of that growth market. Also as previously discussed, the effects of the Medicare legislation is likely to have a very positive impact going forward, on companies such as Ferraris.

Regards wan ;-)